Abstract: A client application is specified by a target tenant and represented in an OAuth provider, along with a corresponding secret. A source tenant consents to permissions to be executed by the client application on a resource of the source tenant. A target service uses the secret to obtain an access token from an authorization server coupled to the source tenant and uses the access token to obtain access, specified by the permissions, to the resource served by a source service acting on behalf of the source tenant.

Abstract: The present disclosure provides devices and methods for the treatment of ophthalmological conditions such as dry eye. Among the devices provided are punctal plugs and devices for inserting punctal plugs. The punctal plugs may be shaped for insertion in the punctum and/or the canaliculus. They may also be coated with a bioadhesive. Methods for inserting the punctal plugs are provided, as well as methods for preparing bioadhesive-coated punctal plugs. A method is also provided to treat dry-eye using a bioadhesive without use of a punctal plug.

Abstract: Access to data and resources in a multi-tenant computing system is managed by tagging the data and resources with attributes, as well as by tagging users with attributes. Tenant-specific access policies are configured. When an access request is received from a workload, a policy decision engine processes the attributes that are tagged to the requesting workload (e.g., user, application, etc.) as well as those tagged to the requested data or resource, given a relevant tenant-specific policy. An access decision is provided in response to the access request, and the access decision can be enforced by a tenant-specific enforcement system.

Abstract: The present disclosure provides devices and methods for the treatment of ophthalmological conditions such as dry eye. Among the devices provided are punctal plugs and devices for inserting punctal plugs. The punctal plugs may be shaped for insertion in the punctum and/or the canaliculus. They may also be coated with a bioadhesive. Methods for inserting the punctal plugs are provided, as well as methods for preparing bioadhesive-coated punctal plugs. A method is also provided to treat dry-eye using a bioadhesive without use of a punctal plug.

Abstract: The present disclosure provides devices and methods for the treatment of ophthalmological conditions such as dry eye. Among the devices provided are punctal plugs and devices for inserting punctal plugs. The punctal plugs may be shaped for insertion in the punctum and/or the canaliculus. They may also be coated with a bioadhesive. Methods for inserting the punctal plugs are provided, as well as methods for preparing bioadhesive-coated punctal plugs. A method is also provided to treat dry-eye using a bioadhesive without use of a punctal plug.

Abstract: The present disclosure provides devices and methods for the treatment of ophthalmological conditions such as dry eye. Among the devices provided are punctal plugs and devices for inserting punctal plugs. The punctal plugs may be shaped for insertion in the punctum and/or the canaliculus. They may also be coated with a bioadhesive. Methods for inserting the punctal plugs are provided, as well as methods for preparing bioadhesive-coated punctal plugs. A method is also provided to treat dryeye using a bioadhesive without use of a punctal plug.

Abstract: A client application is specified by a target tenant and represented in an OAuth provider, along with a corresponding secret. A source tenant consents to permissions to be executed by the client application on a resource of the source tenant. A target service uses the secret to obtain an access token from an authorization server coupled to the source tenant and uses the access token to obtain access, specified by the permissions, to the resource served by a source service acting on behalf of the source tenant.

Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Abstract: A client application is specified by a target tenant and represented in an OAuth provider, along with a corresponding secret. A source tenant consents to permissions to be executed by the client application on a resource of the source tenant. A target service uses the secret to obtain an access token from an authorization server coupled to the source tenant and uses the access token to obtain access, specified by the permissions, to the resource served by a source service acting on behalf of the source tenant.

Abstract: A heated medical face mask is provided, including, a first outer layer having an outer surface and an inner surface; a second, inner layer having an outer surface and in inner surface; the first and second layers being fastened together around corresponding peripheral side and bottom edges but being open along an upper edge or side edge to form a pocket; and a heating element being releasably located in the pocket.

Abstract: A client application is specified by a target tenant and represented in an OAuth provider, along with a corresponding secret. A source tenant consents to permissions to be executed by the client application on a resource of the source tenant. A target service uses the secret to obtain an access token from an authorization server coupled to the source tenant and uses the access token to obtain access, specified by the permissions, to the resource served by a source service acting on behalf of the source tenant.

Abstract: Access to data and resources in a multi-tenant computing system is managed by tagging the data and resources with attributes, as well as by tagging users with attributes. Tenant-specific access policies are configured. When an access request is received from a workload, a policy decision engine processes the attributes that are tagged to the requesting workload (e.g., user, application, etc.) as well as those tagged to the requested data or resource, given a relevant tenant-specific policy. An access decision is provided in response to the access request, and the access decision can be enforced by a tenant-specific enforcement system.

Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition, to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Abstract: The present disclosure provides devices and methods for the treatment of ophthalmological conditions such as dry eye. Among the devices provided are punctal plugs and devices for inserting punctal plugs. The punctal plugs may be shaped for insertion in the punctum and/or the canaliculus. They may also be coated with a bioadhesive. Methods for inserting the punctal plugs are provided, as well as methods for preparing bioadhesive-coated punctal plugs. A method is also provided to treat dryeye using a bioadhesive without use of a punctal plug.

Abstract: A garment for regulating temperature is provided, with a body including a back panel and at least one front panel and at least partially joined along at least one common edge, an inner liner panel fastened to an inner surface of at least one of the back panel and to the at least one front panel with a first surface, and a second surface opposite to the first surface of the inner liner panel, and at least one pocket with top, bottom and side edges, being fastened to at least one of the first and second surfaces of the inner removable liner panel. The at least one pocket has at least one side opening.

Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Abstract: A garment for regulating temperature is provided, with a body including a back panel and at least one front panel and at least partially joined along at least one common edge, an inner liner panel fastened to an inner surface of at least one of the back panel and to the at least one front panel with a first surface, and a second surface opposite to the first surface of the inner liner panel, and at least one pocket with top, bottom and side edges, being fastened to at least one of the first and second surfaces of the inner removable liner panel. The at least one pocket has at least one side opening.